What Are The Side Effects Of Cosentyx
The most common side effects reported include upper respiratory tract infections, headache, cold sores, nausea, fatigue and diarrhoea. Many side effects of Cosentyx are mild and do not cause most people to stop taking it.
Although side effects are possible with this, and any treatment, it is important to remember that people taking Cosentyx have regular blood tests to check for health issues. If a serious infection occurs a doctor will most likely stop Cosentyx. If you are worried about the side effects of Cosentyx, you should discuss these with your doctor or specialist nurse.
What Drugs Interact With Cosentyx
Cosentyx may interact with warfarin, cyclosporine, or “live” vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Cosentyx. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
How Should Humira Be Taken
Humira is given by an injection under the skin. Your doctor will tell you how often to take an injection of Humira. This is based on your condition to be treated. Do not inject Humira more often than you were prescribed.
Do not try to inject Humira yourself until you have been shown the right way to give the injections. If your doctor decides that you or a caregiver may be able to give your injections of Humira at home, you should receive training on the right way to prepare and inject Humira.
Do not miss any doses of Humira unless your doctor says it is okay. If you forget to take Humira, inject a dose as soon as you remember. Then, take your next dose at your regular scheduled time. This will put you back on schedule.
In case you are not sure when to inject Humira, call your doctor or pharmacist.
If you take more Humira than you were told to take, call your doctor.
Also Check: What Can Cause Gouty Arthritis
How Does Cosentyx Work
Cosentyx binds to a cytokine called interleukin-17A , which is involved in the bodys inflammatory and immune responses. There are higher levels of IL-17A in psoriatic plaques than in non-psoriatic skin. By binding to IL-17A, Cosentyx inhibits its action . This means Cosentyx interrupts the inflammatory cycle of psoriasis, which can lead to the improvement in symptoms for many people who take it.
Because of the effect Cosentyx has on the immune system, you will be monitored for infections throughout treatment, and you will be tested for latent TB before starting treatment. People taking Cosentyx may need an annual flu jab, but should check with a doctor or nurse before having any other vaccinations or taking other medication.
Granuloma Annulare And Related Cutaneous Granulomatous Conditions
Chen and associates stated that granuloma annulare , a benign inflammatory skin disease, is considered a Th1-type delayed hypersensitivity reaction. Localized GA is likely to resolve spontaneously, whereas disseminated GA may persist for decades and can be resistant to treatment. Biologics including TNF- inhibitors have been proposed and utilized as salvage therapy for GA and other related diseases, actinic granuloma , and interstitial granulomatous dermatitis . These investigators carried out a systematic review using the combination of search terms “granuloma annulare”, “interstitial granulomatous dermatitis”, or “actinic granuloma” and either “biologics”, “etanercept”, “adalimumab”, “infliximab”, “ustekinumab”, “ixekizumab”, “secukinumab”, “guselkumab”, “golimumab”, “brodalumab”, “tildrakizumab” or “certolizumab” from 1970 to 2017. Review of the literature revealed that 79.3 % of the patients with GA, IGD, or AG who had been treated with TNF- inhibitor therapy showed a clinical response. The authors concluded that TNF- inhibitor therapy has been used to treat chronic GA, IGD, and AG that involved extensive BSA. However, the literature is limited to case series lacking control groups. These researchers stated that RCTs are needed to establish evidence-based treatment of GA and related cutaneous, granulomatous conditions.
Also Check: Is Turkey Bad For Arthritis
Who Cosentyx Is Prescribed For
Cosentyx is approved to treat moderate to severe plaque psoriasis. The condition is considered moderate to severe if it covers 3% or more of your body. For reference, 1% of your body is about the size of your hand .
You must be able to have or systemic therapy. With phototherapy, light treats psoriasis plaques. Systemic therapy works in your whole body to stop the formation of plaques.
Cosentyx is also approved to treat active psoriatic arthritis. When the condition is active, you currently have symptoms.
Clinical trials have shown Cosentyx to be effective for treating psoriasis, including plaque psoriasis and psoriatic arthritis.
For treating plaque psoriasis, researchers looked at adults with moderate to severe plaque psoriasis. The researchers gave them either Cosentyx or a placebo . In 12 weeks, more adults who received Cosentyx reported that their symptoms eased than adults who received a placebo.
Researchers also compared Cosentyx with a placebo for treating adults with psoriatic arthritis. After 16 weeks, more adults who received Cosentyx reported that their symptoms eased than people who received a placebo.
Guidelines
Guidelines published by the American Academy of Dermatology recommend secukinumab, the active drug in Cosentyx, as a treatment option for adults with moderate to severe plaque psoriasis.
Trials 1 And : The Erasure And Fixture Studies
The ERASURE study was a 52-week, randomized, placebo-controlled trial that included 738 patients who received subcutaneous therapy at weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks. Patients were randomized to secukinumab 300-mg or 150-mg doses for the first 4 weeks, followed by the same dose every 4 weeks, or to placebo.,
The FIXTURE study , also a 52-week, randomized, placebo-controlled trial, included 1306 patients 327 patients received secukinumab 300 mg, 327 patients received secukinumab 150 mg, 326 patients received placebo, and 323 patients received a biologic active control ., This discussion is limited to the data related to the secukinumab and the placebo groups.
The results of Trials 1 and 2 are shown in . In both studies, a greater proportion of patients who received secukinumab than those who received placebo or a biologic control met the PASI 75 criterion at week 12. At week 12 of Trial 1, a PASI 90 response was achieved in 59% of the secukinumab 300-mg group, 39% of the 150-mg group, and only 1% of the placebo group. At the same point in Trial 2, a PASI 90 response was achieved in 54% and 42% of the secukinumab groups versus 2% of the placebo group. The investigators concluded that the effectiveness of secukinumab in these trials validated IL-17A as a therapeutic target.
Don’t Miss: How To Treat Arthritis In Lumbar Spine
How Often To Use
The dosing schedule of Cosentyx varies depending on which condition youre using Cosentyx to treat. Youll use Cosentyx either once a week or once every 4 weeks. Its best if you take Cosentyx on the same day every week or month.
To help make sure that you dont miss a dose, try putting your treatment schedule in your calendar. You can also try setting a reminder on your phone.
Who Should Not Take Cosentyx
- People with active, serious infections. You will be tested to check for infections before starting treatment.
- Pregnant women should not be treated with Cosentyx and women should not fall pregnant for at least 20 weeks after treatment has stopped. You should not breastfeed whilst taking Cosentyx for at least 20 weeks after treatment has stopped.
- Caution is advised in people with Crohns Disease, as Cosentyx has been shown to exacerbate Crohns Disease in some cases.
- Caution is also advised for those with a latex allergy , and for those with already impaired immune systems
- Children or adolescents with psoriatic arthritis because it has not been studied in this age group for this condition
Read Also: What Is The Best Medication To Treat Rheumatoid Arthritis
Cosentyx A New Treatment Option For Plaque Psoriasis
On January 21, 2015, secukinumab , a human IL-17A antagonist, was approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis. Secukinumab, a biologic immunomodulator drug administered by subcutaneous injection, is indicated for patients who are candidates for systemic therapy or phototherapy or a combination of both therapies., Secukinumab is the first IL-17A to receive FDA approval for the treatment of patients with moderate-to-severe plaque psoriasis.
As part of its approval, the FDA required the manufacturer to include a medication guide to inform patients that because secukinumab affects the immune system, it may increase the risk for infection.
Commenting on this approval, Amy Egan, MD, MPH, the FDA’s Deputy Director of the Office of Drug Evaluation III, said, Plaque psoriasis can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients.
On January 15, 2016, the FDA approved 2 new indications for secukinumabfor the treatment of adults with active ankylosing spondylitis, and for the treatment of adults with active psoriatic arthritis.
Tremfya Already Approved For Psoriasis Inhibits An Immune System Protein Called Il
Psoriatic arthritis may be treated with a wide variety of medications, from NSAIDs that focus on pain relief to disease-modifying drugs and biologics aimed at actually slowing the progression of this inflammatory condition. While many of the biologics used for psoriatic arthritis block an immune system protein called tumor necrosis factor , PsA patients have in recent years gained access to a growing number of drugs that target types of interleukin, another inflammatory protein.
In 2016, the FDA approved secukinumab , which targets IL-17A. In 2017, the agency approved ixekizumab , which also blocks IL-17A.
Now the FDA has approved a different interleukin blocker, but this one targets IL-23 instead.
Already approved for psoriasis, guselkumab is now the first IL-23 inhibitor to be FDA-approved for the treatment of psoriatic arthritis.
Another medication that targets both IL-23 and IL-12, ustekinumab has been approved to treat PsA since 2013.
Tremfya, which is taken via subcutaneous injection, can be used alone or along with a traditional DMARD such as methotrexate. According to Janssen, the drugs manufacturer, FDA approval for psoriatic arthritis was granted after two phase 3 clinical trials demonstrated that patients with active PsA who used it were more likely to have improvements in disease activity compared to those who took a placebo.
Whether or not Tremfya is more effective than other biologics for PsA is unclear.
Recommended Reading: Is Cheese Bad For Arthritis
Cosentyx Stops Or Lessens Psoriatic Arthritis Symptoms Studies Show
A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.
Secukinumab can stop radiographic progression of psoriatic arthritis in almost 90% of patients and lessen axial manifestations, according to a new pair of studies.
PsA affects an estimated 50 million people worldwide alongside other inflammatory diseases that are in the same family. It can start at any age, but usually presents itself between ages 30-50, approximately a decade after psoriasis begins. Currently, while symptoms of inflammation in the joints can be treated, there is no cure.
Cosentyx is currently the only fully-human biologic that directly inhibits interleukin-17A , a key cytokine in PsA development and inflammation. It was first recommended for approval for treating plaque psoriasis by the US Food and Drug Administration in 2014, then officially approved along those lines in 2015.
In 2016, it was also approved for use in ankylosing spondylitis and psoriatic arthritis. Having undergone a trio of 5-year phase 3 extension studies, Cosentyx has since treated over 200,000 patients globally since its launch.
Cosentyx inhibited radiographic progression for the majority of patients in the FUTURE 5 trial: 89.5% at 300 mg, 82.3% at 150 mg, and 81.1% at 150mg with no loading dose. Radiographic damage is characterized by joint inflammation, erosion, and joint space narrowing, especially in hands and feet.
Before Using This Medicine
You should not use Cosentyx if you are allergic to secukinumab.
Tell your doctor if you’ve had or been exposed to tuberculosis, or if you recently traveled. Some infections are more common in certain parts of the world, and you may have been exposed during travel.
To make sure you can safely use Cosentyx, tell your doctor if you have ever had:
-
an active or chronic infection
-
an allergy to latex or
-
if you currently have signs of infection such as fever, sweats, chills, muscle pain, cough, shortness of breath, cough with bloody mucus, weight loss, skin sores, stomach pain, diarrhea, or painful urination.
Make sure you are current on all vaccines before you start using Cosentyx.
Tell your doctor if you are pregnant or breastfeeding.
Recommended Reading: Do You Get Arthritis In Your Feet
How Long Does Cosentyx Take To Work For Psoriasis
How long Cosentyx takes to work for plaque psoriasis and psoriatic arthritis depends on which condition the drug is treating. Clinical trials showed that:
- For treating plaque psoriasis, people taking Cosentyx reported that their symptoms eased in 12 weeks of treatment.
- For treating psoriatic arthritis, people taking Cosentyx reported that their symptoms eased after 16 weeks. Some people taking Cosentyx reported symptom relief in as few as 3 weeks.
Its important to remember that each persons body will react differently to Cosentyx. You may see results more quickly or more slowly. If you have questions about how well Cosentyx is working for you, talk with your doctor. They can help answer questions you may have about whether Cosentyx is effective for your condition.
Use In Specific Populations
Because it is not known whether secukinumab is excreted in human milk, caution is advised when secukinumab is administered to a nursing woman.9
Of the 3430 patients with plaque psoriasis who received secukinumab in clinical trials, 230 patients were aged 65 years and 32 were aged 75 years.9 No differences in the safety or efficacy of secukinumab were observed between patients in these age-groups and younger patients however, the number of older patients was insufficient to assess a definitive difference between the 2 age-groups.9
You May Like: Is Malt Vinegar Good For Arthritis
The Way Cosentyx Works
Cosentyx is classified as a monoclonal antibody. Monoclonal antibodies are proteins that work through your immune system, which is your bodys defense against infection.
Your immune system makes special types of proteins that can cause inflammation. Interleukin 17A is one of these proteins. Its been found to contribute to both plaque psoriasis and psoriatic arthritis. IL-17A can make symptoms of psoriasis worse. Researchers have found that people with plaque psoriasis and psoriatic arthritis have higher blood levels of IL-17A than people without these conditions.
The way Cosentyx works is to bind to IL-17A and prevent it from working. By preventing IL-17A from acting, Cosentyx helps decrease inflammation in your body. Inflammation leads to swelling and damage, which worsens plaque psoriasis and psoriatic arthritis. Because Cosentyx can prevent swelling and damage from occurring, the drug should help ease your symptoms.
How Safe And Effective Is Cosentyx
Cosentyx has been used to treat psoriasis in the UK since 2015. Real-world safety and effectiveness data is being compiled by the British Association of Dermatologists Biologics and Immunomodulators Register and the British Society for Rheumatology Psoriatic Arthritis Register . The National Institute for Health and Care Excellence recommends that all patients receiving biologic therapy, who provide their consent, are entered onto these observational study registers.
The information on this page is not intended to replace that of a healthcare professional: If you have any concerns or questions about your treatment, do discuss this with your doctor and always read the patient information leaflet to make sure you are using them correctly.
For more information, or for a list of resources used in the production of this information sheet, please contact the Psoriasis Association.
Don’t Miss: What Over The Counter Is Good For Arthritis
How Should I Use Cosentyx
Use Cosentyx exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
Cosentyx is injected under the skin.
Ask your doctor or pharmacist if you don’t understand how to use an injection.
Prepare an injection only when you are ready to give it. You may need to use 2 injections to get your total dose.
Cosentyx should be clear or light-yellow. Call your pharmacist if the liquid Cosentyx in your vial, pen, or syringe looks cloudy, has changed colors, or has particles in it.
Your healthcare provider will show you where to inject Cosentyx. Do not inject into the same place two times in a row. Avoid injecting into skin that is hard, red, bruised, swollen, tender, or affected by psoriasis. Do not inject within 2 inches of your navel .
You may get infections more easily, even serious infections. You will need frequent medical tests.
Do not reuse a needle or syringe. Place them in a puncture-proof “sharps” container and dispose of it following state or local laws. Keep out of the reach of children and pets.
Store Cosentyx in the original container in a refrigerator. Protect from light and do not shake or freeze.
Take the injection pen out of the refrigerator and let it reach room temperature for 15 to 30 minutes before using. Give the injection within 1 hour after removing the medicine from a refrigerator.
Cosentyx Gets First Us Approval In Children
The US Food and Drug Administration has approved Cosentyx for the treatment of moderate
To continue reading The Pharma Letter please , or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic , then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Recommended Reading: What Age Does Psoriatic Arthritis Start